ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Actinium Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$1.32+0.19 (+16.81%)
Close on Oct 19, 2026
- Market cap
- $41.46M
- P/E (TTM)
- 3.7
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2015 Ended Jun 30, 2015 | Aug 3, 2015 | Before market open | – | – | – |
Press releases
Announcements Actinium Pharmaceuticals filed with the SEC
PRESS RELEASE DATED OCTOBER 15, 2026
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED AUGUST 14, 2026
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 29, 2026
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED NOVEMBER 4, 2024.
Executive or director change · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED AUGUST 5, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 18, 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
INVESTOR PRESENTATION, DATED FEBRUARY 18, 2023
Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE, DATED OCTOBER 31, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K